Get Started in Minutes
How Zarxio Copay Assistance Works
1 – Check Your Coverage/Benefits Verification
Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.
2 – Transfer Prescription to AmeriPharma
We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.
3 – Prior Authorization
Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.
4 – Copay Assistance & Financial Aid
We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma Specialty Care has secured $55 million in financial assistance for our patients.
5 – Nursing Care Coordination
AmeriPharma puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.
6 – Delivery Coordination
Medications are always delivered in strict compliance with the specific requirements for immune globulin shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.
What Is Zarxio?
Filgrastim is also known by the brand name Neupogen. Other available biosimilars include Zarxio, Granix, and Nivestym. Neupogen was the first medication produced based on the active element, filgrastim. These drugs have been used successfully for cancer patients to stimulate the growth of white blood cells.
Based on Neupogen, Zarxio became the first biosimilar product available in the United States in March 2015. Thus, Zarxio is similar to Neupogen in its mechanism of action, administration route, strength, and dosage. The difference between the formulation of the two agents is in one inactive component.
How Is Zarxio Used?
Zarxio has been approved by the Food and Drug Administration (FDA) for the treatment of severe long-standing neutropenia and neutropenia caused by chemotherapy. It has also been approved for use prior to and after a stem cell or bone marrow transplantation, and for patients with acute myeloid leukemia (AML) on induction chemotherapy.
Zarxio is only available as injections given subcutaneously (under the skin) or intravenously (IV). Zarxio is available as a single-use prefilled syringe for subcutaneous injection in two doses: 300 mcg/0.5 ml and 480 mcg/0.8 ml.
If you miss a dose, contact your physician immediately to reschedule.
Store Zarxio in the refrigerator and avoid freezing. If frozen, thaw in the refrigerator before use. Zarxio should be thawed (taken out of the refrigerator) at room temperature for 30 minutes before use. It can be left at room temperature for up to 24 hours. Do not shake the vials and keep them protected from light by storing them in their original containers.
Copay and Financial Assistance
AmeriPharma Specialty Care alleviates financial burdens for patients and their families
Advanced software locates funding sources to match you with top-dollar foundation programs
One of our copay assistance specialists will assist with the application process
Automatic updates will be sent to you and your physician on the status of the funding
Zarxio Side Effects
Serious side effects include:
- Bone and muscle aches
- Thrombocytopenia, leukocytosis
- Lung problem called acute respiratory distress syndrome (ARDS)
- Kidney injury
- Capillary leak syndrome
- Inflammation of blood vessels
- Rupture of the spleen
Less serious side effects include:
Unless approved by your physician, Zarxio is generally not recommended in:
- Patients who have an allergy to human granulocyte colony-stimulating factors (CFS) such as filgrastim or pegfilgrastim products: Allergic reactions can cause a rash over the whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating. If you have any of these symptoms, stop using Zarxio, and call your doctor or get emergency help right away.
- Patients with sickle cell disorder: Using Zarxio can lead to a condition called sickle cell crisis, which may be life-threatening.
- Patients receiving radiation therapy: Zarxio may increase the risk of developing a precancerous condition called myelodysplastic syndrome (MDS) or a type of blood cancer called acute myeloid leukemia (AML).
Pregnancy and Zarxio
Pregnant women, women who are planning to become pregnant, and breastfeeding women must consult a physician prior to initiating Zarxio. The risk to the fetus or baby is unknown.